Natreon Granted U.S. Patent for Crominex3+

Natreon has been granted a U.S. Patent (10,183,047, January 22, 2019) on its Crominex3+, a composition of trivalent chromium chloride combined with extracts of amla and shilajit, that has a synergistic effect on improving lipid profile and endothelial function. This newly granted patent, along with seven clinical studies on Crominex3+, establish this ingredient as a product for supporting heart health. This expands Natreon’s patent portfolio to 28 domestic and international active patents.

“We are glad that USPTO has granted a well-deserved patent for cardiovascular health benefits of Crominex3+, the most efficacious of several chromium supplements from the market. Crominex3+ has amazing synergistic activity that showed significant improvement in endothelial function, lipid profile, hsCRP, as well as HbA1c, which are all important factors for cardiovascular health. Synergistic activity of Crominex3+ is achieved by using totally natural materials,” said Dr. Sanni Raju, CEO of Natreon.

Two additional clinical studies (to be published soon), show combining only 10-20 mg of Crominex3+ (200 mcg to 400 mcg of trivalent chromium) with 2 g of fish oil (600 mg of EPA + 400 mg of DHA) enhances the health benefits of fish oil significantly.

“It is interesting to note that 10-20 mg of Crominex3+ neither increases the size of the fish oil dosage form nor impacts the cost significantly while enhancing fish oil’s numerous cardiovascular health benefits,” said Raju.